<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="172250">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853866</url>
  </required_header>
  <id_info>
    <org_study_id>2005-00160436-36</org_study_id>
    <secondary_id>28/2005AMG1</secondary_id>
    <secondary_id>IMPACS-01</secondary_id>
    <nct_id>NCT00853866</nct_id>
  </id_info>
  <brief_title>Enhancement of Motor Function With Reboxetine and Transcranial Direct Current Stimulation</brief_title>
  <acronym>STIMBOX</acronym>
  <official_title>Entwicklung Neuronaler Repräsentationen Nach Schlaganfall: Verbesserung Motorischer Leistungen Durch Transkranielle Gleichstromstimulation Und Noradrenerge Co-Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the study is that combination of reboxetine/tDCS is more effective in
      enhancing motor functions of daily life (assessed by the Jebsen Taylor test) as compared to
      reboxetine and tDCS alone. The protocol is designed as a within-subject, block randomized
      placebo-controlled double-blind crossover study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One important feature of the human brain is the ability to undergo plastic changes and
      reorganization after learning and lesions of the nervous system. This ability is of major
      importance for the treatment of functional deficits after stroke. Stroke is the major
      disease leading to persistent functional disabilities in Germany. However, the success rate
      of therapeutic interventions, especially in chronic stroke patients, is still
      unsatisfactory. Thus, basic science is essential to discover new therapeutic options that
      bear the potential for translation into clinical practice. Recent evidence is pointing to
      modulating the motor cortical excitability in order to enhance motor function in stroke
      patients. For this purpose, reboxetine as a selective reuptake inhibitor of noradrenaline
      and transcranial direct current stimulation have proven effective in enhancing motor
      functions needed for daily life activities by 10-12%. These improvements were significant
      compared to placebo, but still clinically unsatisfactory. Thus, this protocol aims at
      enhancing the excitability modulatory effect of each single intervention through the
      combination of reboxetine and tDCS. The hypothesis of the study is that combination of
      reboxetine/tDCS is more effective in enhancing motor functions of daily life (assessed by
      the Jebsen Taylor test) as compared to reboxetine and tDCS alone.

      The protocol is designed as a within-subject, block randomized placebo-controlled
      double-blind crossover study. 12 chronic stroke patients with persistent functional deficits
      of the arm and/or hand will be included. The primary outcome measure is the time needed to
      fulfill all subtests of the Jebsen Taylor test. All patients undergo four different
      conditions in four different sessions: 1) reboxetine + verum tDCS; 2) reboxetine + sham tDCS
      3) placebo drug + verum tDCS 4) placebo drug + sham tDCS.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Jebsen Taylor test</measure>
    <time_frame>crossover design, four different sessions with four different interventions</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum grip force</measure>
    <time_frame>crossover design, four different sessions with four different interventions</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nine hole peg test</measure>
    <time_frame>crossover design, four different sessions with four different interventions</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cerebral Stroke</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>reboxetine + tDCS verum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>reboxetine + sham tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo drug + verum tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo drug + sham tDCS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reboxetine</intervention_name>
    <description>single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>brand name: Edronax, serial number: KPR 08092410/11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo, 80 min before assessment of Jebsen Taylor test</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS verum</intervention_name>
    <description>20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Hersteller:</other_name>
    <other_name>DC Stimulator</other_name>
    <other_name>Manufacturer:</other_name>
    <other_name>eldith -Electro-Diagnostic &amp; Therapeutic Systems GmbH</other_name>
    <other_name>Gustav-Kirchhoff-Straße 5</other_name>
    <other_name>D-98693 Ilmenau</other_name>
    <other_name>Serialnumber: 0006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS sham</intervention_name>
    <description>30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Hersteller:</other_name>
    <other_name>DC Stimulator</other_name>
    <other_name>Manufacturer:</other_name>
    <other_name>eldith -Electro-Diagnostic &amp; Therapeutic Systems GmbH</other_name>
    <other_name>Gustav-Kirchhoff-Straße 5</other_name>
    <other_name>D-98693 Ilmenau</other_name>
    <other_name>Serialnumber: 0006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 86

          -  patient is contractually capable

          -  first-ever, ischemic stroke

          -  minimum time since stroke 9 months

          -  a paresis of the arm/hand muscles above 3 on the MRC scale

        Exclusion Criteria:

          -  multiple cerebral lesions and associated residual deficits

          -  severe head trauma in the past

          -  seizures

          -  ferromagnetic implants in the head/neck region

          -  pacemaker

          -  a psychiatric disorder or neurological disease besides stroke

          -  intake of illegal drugs

          -  severe aphasia or cognitive deficits that impede contractual capability

          -  contraindications for reboxetine (seizures, glaucoma, prostate hyperplasia with
             urinary retention, cardiac arrhythmias, potential interactions with co-medication)

          -  pregnancy

          -  breast-feeding patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Gerloff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University Hospital Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianpiero Liuzzi, MD</last_name>
    <phone>+49 40 7410</phone>
    <phone_ext>59278</phone_ext>
    <email>g.liuzzi@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Gerloff, MD</last_name>
    <phone>+ 49 40 7410</phone>
    <phone_ext>53770</phone_ext>
    <email>gerloff@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf, Department of Neurology</name>
      <address>
        <city>Hamburg</city>
        <state>HH</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianpiero Liuzzi, MD</last_name>
      <phone>+49 40 7410</phone>
      <phone_ext>59278</phone_ext>
      <email>g.liuzzi@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian Gerloff, MD</last_name>
      <phone>+49 40 7410</phone>
      <phone_ext>53770</phone_ext>
      <email>gerloff@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gianpiero Liuzzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Gerloff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Hoppe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Friedhelm C Hummel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kirstin F Heise, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Hummel F, Celnik P, Giraux P, Floel A, Wu WH, Gerloff C, Cohen LG. Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke. Brain. 2005 Mar;128(Pt 3):490-9. Epub 2005 Jan 5.</citation>
    <PMID>15634731</PMID>
  </reference>
  <reference>
    <citation>Hummel F, Cohen LG. Improvement of motor function with noninvasive cortical stimulation in a patient with chronic stroke. Neurorehabil Neural Repair. 2005 Mar;19(1):14-9.</citation>
    <PMID>15673839</PMID>
  </reference>
  <reference>
    <citation>Hummel FC, Voller B, Celnik P, Floel A, Giraux P, Gerloff C, Cohen LG. Effects of brain polarization on reaction times and pinch force in chronic stroke. BMC Neurosci. 2006 Nov 3;7:73.</citation>
    <PMID>17083730</PMID>
  </reference>
  <reference>
    <citation>Plewnia C, Hoppe J, Gerloff C. No effects of enhanced central norepinephrine on finger-sequence learning and attention. Psychopharmacology (Berl). 2006 Aug;187(2):260-5. Epub 2006 Jun 10.</citation>
    <PMID>16767410</PMID>
  </reference>
  <reference>
    <citation>Plewnia C, Hoppe J, Cohen LG, Gerloff C. Improved motor skill acquisition after selective stimulation of central norepinephrine. Neurology. 2004 Jun 8;62(11):2124-6.</citation>
    <PMID>15184632</PMID>
  </reference>
  <reference>
    <citation>Plewnia C, Hoppe J, Hiemke C, Bartels M, Cohen LG, Gerloff C. Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine. Neurosci Lett. 2002 Sep 27;330(3):231-4.</citation>
    <PMID>12270635</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>December 1, 2010</lastchanged_date>
  <firstreceived_date>February 27, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Prof. Dr. C. Gerloff</name_title>
    <organization>Department of Neurology, University Hospital Hamburg-Eppendorf</organization>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>reboxetine</keyword>
  <keyword>noradrenaline</keyword>
  <keyword>motor cortex</keyword>
  <keyword>transcranial direct current stimulation</keyword>
  <keyword>motor function</keyword>
  <keyword>rehabilitation</keyword>
  <keyword>Jebsen Taylor test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Reboxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
